{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:48Z","timestamp":1790767848338,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["3165-00013 B"],"award-info":[{"award-number":["3165-00013 B"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007371","name":"Svend Andersen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.pan.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:50:52Z","timestamp":1741031452000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tocilizumab for Painful Chronic Pancreatitis (TOPAC trial): Protocol for a phase 2 randomized, placebo-controlled, double-blind, investigator-initiated trial"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-755X","authenticated-orcid":false,"given":"Rasmus","family":"Hagn-Meincke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-0070","authenticated-orcid":false,"given":"Jens Br\u00f8ndum","family":"Fr\u00f8kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7465-964X","authenticated-orcid":false,"given":"Asbj\u00f8rn Mohr","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Henneberg","family":"Holmboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Krogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-1408","authenticated-orcid":false,"given":"Rasmus Bach","family":"Nedergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-8144","authenticated-orcid":false,"given":"Line","family":"Davidsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2659-4313","authenticated-orcid":false,"given":"Tina","family":"Okdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-7564","authenticated-orcid":false,"given":"Ingfrid Salvesen","family":"Haldorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-4188","authenticated-orcid":false,"given":"Walter","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-1587","authenticated-orcid":false,"given":"Bent Winding","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3916-3168","authenticated-orcid":false,"given":"S\u00f8ren Schou","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2025.03.001_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.60","article-title":"Chronic pancreatitis","volume":"3","author":"Kleeff","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(16)30004-8","article-title":"Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies","volume":"1","author":"Xiao","year":"2016","journal-title":"Lancet Gastroenterol Hepatol [Internet]"},{"issue":"3","key":"10.1016\/j.pan.2025.03.001_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41575-018-0087-5","article-title":"Global epidemiology and holistic prevention of pancreatitis","volume":"16","author":"Petrov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol [Internet]"},{"issue":"24","key":"10.1016\/j.pan.2025.03.001_bib4","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1001\/jama.2019.19411","article-title":"Diagnosis and management of chronic pancreatitis: a review","volume":"322","author":"Singh","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pan.2025.03.001_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.14309\/ajg.0000000000000147","article-title":"Chronic pancreatitis is characterized by distinct complication clusters that associate with etiological risk factors","volume":"114","author":"Olesen","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.pan.2025.03.001_bib6","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-20-0974","article-title":"Diagnosing and classifying diabetes in diseases of the exocrine pancreas","volume":"184","author":"Petrov","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.pan.2025.03.001_bib7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pan.2025.03.001_bib8","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1038\/ncomms8158","article-title":"Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis","volume":"6","author":"Xue","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.pan.2025.03.001_bib9","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/MPA.0000000000000896","article-title":"Local and systemic expression of immunomodulatory factors in chronic pancreatitis","volume":"46","author":"Komar","year":"2017","journal-title":"Pancreas"},{"issue":"October","key":"10.1016\/j.pan.2025.03.001_bib10","first-page":"1","article-title":"Immune response mechanisms in acute and chronic pancreatitis: strategies for therapeutic intervention","volume":"14","author":"Glaubitz","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pan.2019.11.008","article-title":"Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: a pilot study of these conditions with and without diabetes","volume":"20","author":"Park","year":"2020","journal-title":"Pancreatology"},{"issue":"2","key":"10.1016\/j.pan.2025.03.001_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MEG.0000000000002691","article-title":"Circulating immune signatures across clinical stages of chronic pancreatitis: a pilot study","volume":"36","author":"Hagn-Meincke","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pan.2025.03.001_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.pan.2024.02.012","article-title":"Circulating immune signatures in chronic pancreatitis with and without preceding acute pancreatitis: a pilot study","volume":"24","author":"Hagn-Meincke","year":"2024","journal-title":"Pancreatology"},{"issue":"5","key":"10.1016\/j.pan.2025.03.001_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.pan.2016.08.004","article-title":"Chronic pancreatitis: do serum biomarkers provide an association with an inflammageing phenotype?","volume":"16","author":"Rasch","year":"2016","journal-title":"Pancreatology"},{"issue":"2","key":"10.1016\/j.pan.2025.03.001_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pain.2010.05.022","article-title":"Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist","volume":"151","author":"Vardanyan","year":"2010","journal-title":"Pain"},{"issue":"19","key":"10.1016\/j.pan.2025.03.001_bib16","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1073\/pnas.1620264114","article-title":"Mathematical model of chronic pancreatitis","volume":"114","author":"Hao","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"3","key":"10.1016\/j.pan.2025.03.001_bib17","first-page":"267","article-title":"Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab","volume":"15","author":"Zielecki","year":"2020","journal-title":"Przegl\u0105d Gastroenterol"},{"issue":"10","key":"10.1016\/j.pan.2025.03.001_bib18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med [Internet]"},{"issue":"6","key":"10.1016\/j.pan.2025.03.001_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol [Internet]"},{"issue":"9617","key":"10.1016\/j.pan.2025.03.001_bib20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"The Lancet [Internet]"},{"issue":"3","key":"10.1016\/j.pan.2025.03.001_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/ncprheum1005","article-title":"Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?","volume":"5","author":"Feist","year":"2009","journal-title":"Nat Rev Rheumatol [Internet]"},{"issue":"9617","key":"10.1016\/j.pan.2025.03.001_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"The Lancet [Internet]"},{"issue":"2","key":"10.1016\/j.pan.2025.03.001_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00535-006-1945-4","article-title":"The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease","volume":"42","author":"Schneider","year":"2007","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.pan.2025.03.001_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pan.2023.01.010","article-title":"Position statement on the definition, incidence, diagnosis and outcome of acute on chronic pancreatitis","volume":"23","author":"Bou\u00e7a-Machado","year":"2023","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2025.03.001_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.108868","article-title":"Progression of parenchymal and ductal findings in patients with chronic pancreatitis: a 4-year follow-up MRI study","volume":"125","author":"Steinkohl","year":"2020","journal-title":"Eur J Radiol"},{"issue":"4","key":"10.1016\/j.pan.2025.03.001_bib26","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1016\/j.cgh.2021.05.055","article-title":"Development of the comprehensive pain assessment Tool short form for chronic pancreatitis: validity and reliability testing","volume":"20","author":"Kuhlmann","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.pan.2025.03.001_bib27","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1572-0241.2005.40859.x","article-title":"Symptoms and quality of life in chronic pancreatitis assessed by structured interview and the EORTC QLQ-C30 and QLQ-PAN26","volume":"100","author":"Fitzsimmons","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.pan.2025.03.001_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpain.2005.06.002","article-title":"Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis","volume":"10","author":"Mendoza","year":"2006","journal-title":"Eur J Pain"},{"issue":"2","key":"10.1016\/j.pan.2025.03.001_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.pan.2025.03.001_bib30","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1053\/j.gastro.2017.08.073","article-title":"Development and validation of a chronic pancreatitis prognosis score in 2 independent cohorts","volume":"153","author":"Beyer","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pan.2025.03.001_bib31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00261-022-03760-6","article-title":"Single- and multiparameter magnetic resonance imaging for diagnosing and severity grading of chronic pancreatitis","volume":"48","author":"Olesen","year":"2023","journal-title":"Abdominal Radiology [Internet]"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pan.2019.11.007","article-title":"A clinically feasible method for the assessment and characterization of pain in patients with chronic pancreatitis","volume":"20","author":"Phillips","year":"2020","journal-title":"Pancreatology"},{"issue":"9","key":"10.1016\/j.pan.2025.03.001_bib33","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/MPA.0000000000001912","article-title":"Rationale for and development of the pancreatic quantitative sensory testing consortium to study pain in chronic pancreatitis","volume":"50","author":"Phillips","year":"2021","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cgh.2020.10.036","article-title":"Pancreatic QST differentiates chronic pancreatitis patients into distinct pain phenotypes independent of psychiatric comorbidities","volume":"20","author":"Faghih","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pan.2025.03.001_bib35","series-title":"EU Clinical Directive 2001\/20\/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations, and administrative provisions of the Member States relating to the implementation of good clinical practice in th","first-page":"184","author":"Council","year":"2010"},{"issue":"July 2020","key":"10.1016\/j.pan.2025.03.001_bib36","volume":"19","author":"Rmp","year":"2020","journal-title":"Eu Rmp for Roactemra"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.gastro.2023.03.236","article-title":"Distinct serum immune profiles define the spectrum of acute and chronic pancreatitis from the multicenter prospective evaluation of chronic pancreatitis for epidemiologic and translational studies (PROCEED) study","volume":"165","author":"Lee","year":"2023","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.pan.2025.03.001_bib38","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jpain.2023.07.006","article-title":"Serum biomarkers of nociceptive and neuropathic pain in chronic pancreatitis","volume":"24","author":"Saloman","year":"2023","journal-title":"J Pain"},{"issue":"8","key":"10.1016\/j.pan.2025.03.001_bib39","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.pan.2021.09.016","article-title":"Serum biomarkers for chronic pancreatitis pain patterns","volume":"21","author":"Saloman","year":"2021","journal-title":"Pancreatology"},{"issue":"5","key":"10.1016\/j.pan.2025.03.001_bib40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/JLB.3A1218-500R","article-title":"The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms","volume":"106","author":"Nielsen","year":"2019","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.pan.2025.03.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2017.554","article-title":"The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis","volume":"8","author":"Staufer","year":"2017","journal-title":"Cell Death Dis"},{"issue":"42","key":"10.1016\/j.pan.2025.03.001_bib42","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.3748\/wjg.v19.i42.7241","article-title":"Morphological and functional evaluation of chronic pancreatitis with magnetic resonance imaging","volume":"19","author":"Hansen","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.pan.2025.03.001_bib43","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0033-8389(02)00056-8","article-title":"MR imaging of the pancreas: a practical approach","volume":"40","author":"Ly","year":"2002","journal-title":"Radiol Clin"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1148\/radiol.2493080160","article-title":"Assessment of chronic pancreatitis: utility of diffusion-weighted MR imaging with secretin enhancement","volume":"250","author":"Akisik","year":"2009","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib45","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MPA.0000000000002388","article-title":"Individualized pain treatment in chronic pancreatitis (INPAIN): an international, multicenter, investigator-initiated, prospective, cohort study","volume":"54","author":"Hagn-Meincke","year":"2025","journal-title":"Pancreas"},{"issue":"December","key":"10.1016\/j.pan.2025.03.001_bib46","first-page":"1","article-title":"Assessment of visceral pain with special reference to chronic pancreatitis","volume":"3","author":"Kuhlmann","year":"2022","journal-title":"Frontiers in Pain Research."},{"issue":"3","key":"10.1016\/j.pan.2025.03.001_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2125.2011.04104.x","article-title":"The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices","volume":"73","author":"Graversen","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pan.2025.03.001_bib48","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.gastro.2023.12.008","article-title":"A randomized controlled phase 2 dose-finding trial to evaluate the efficacy and safety of Camostat in the treatment of painful chronic pancreatitis: the TACTIC study","volume":"166","author":"Hart","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pan.2022.12.008","article-title":"The phase 1\/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): protocol for a parallel multi-center randomized controlled trial","volume":"23","author":"Han","year":"2023","journal-title":"Pancreatology"},{"issue":"3","key":"10.1016\/j.pan.2025.03.001_bib50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10620-008-0390-z","article-title":"Clinical significance of interleukin-6 (Il-6) gene polymorphism and il-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis","volume":"54","author":"Talar-Wojnarowska","year":"2009","journal-title":"Dig Dis Sci [Internet]"},{"issue":"10038","key":"10.1016\/j.pan.2025.03.001_bib51","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2025.03.001_bib52","first-page":"1","volume":"2010","author":"Of","year":"2010","journal-title":"Summary Review - Tocilizumab"},{"issue":"0","key":"10.1016\/j.pan.2025.03.001_bib53","first-page":"1","volume":"44","year":"2021","journal-title":"Summary overview of Tocilizumab"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofab608","article-title":"Safety and efficacy of tocilizumab 4 or 8 mg\/kg in hospitalized patients with moderate to severe coronavirus disease 2019 pneumonia: a randomized clinical trial","volume":"9","author":"Kumar","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","article-title":"A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid art","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis [Internet]"},{"issue":"5","key":"10.1016\/j.pan.2025.03.001_bib56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MOG.0000000000000195","article-title":"Inflammation in acute and chronic pancreatitis","volume":"31","author":"Habtezion","year":"2015","journal-title":"Curr Opin Gastroenterol [Internet]"},{"issue":"6","key":"10.1016\/j.pan.2025.03.001_bib57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd1109","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"2","author":"Smolen","year":"2003","journal-title":"Nat Rev Drug Discov [Internet]"},{"issue":"23","key":"10.1016\/j.pan.2025.03.001_bib58","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pan.2025.03.001_bib59","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug the","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.pan.2025.03.001_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","article-title":"Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition t","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.pan.2025.03.001_bib61","first-page":"689","article-title":"Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis","volume":"29","author":"Greisen","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.pan.2025.03.001_bib62","series-title":"Circulating biomarkers of macrophage activation in different stages of chronic pancreatitis: a pilot study","author":"Hagn-meincke","year":"2024"},{"issue":"7","key":"10.1016\/j.pan.2025.03.001_bib63","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/MPA.0b013e31829628f4","article-title":"Fibrosis, atrophy, and ductal pathology in chronic pancreatitis are associated with pancreatic function but independent of symptoms","volume":"42","author":"Fr\u00f8kj\u00e6r","year":"2013","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.pan.2025.03.001_bib64","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/jmri.27626","article-title":"Evaluation of pancreatic fibrosis grading by multiparametric quantitative magnetic resonance imaging","volume":"54","author":"Liu","year":"2021","journal-title":"J Magn Reson Imag"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:00:11Z","timestamp":1762545611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390325000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1424390325000444"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2025.03.001","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab for Painful Chronic Pancreatitis (TOPAC trial): Protocol for a phase 2 randomized, placebo-controlled, double-blind, investigator-initiated trial","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}